Therapeutic-area Dossier
Gastroenterology
Therapeutic-area Dossier for Gastroenterology (digestive system medicines). Australian brands, active ingredients, PBS-listed treatments, PBAC outcomes —…
- Brand: APO-DOMPERIDONE
- Brand: APO-METOCLOPRAMIDE
- Brand: ASACOL
- Brand: AUSFAM
- Brand: BUDENOFALK
- Brand: COLAZIDE
- Sponsor: Arrotex Pharmaceuticals
- Sponsor: Sun Pharma
- Sponsor: Torrent
- Sponsor: Alphapharm
What is
Gastroenterology Gastroenterology covers 339 registered brands in Australia, addressing therapeutic needs across the digestive system including conditions affecting the oesophagus, stomach, intestines and related organs. The area encompasses a broad range of treatments from acid-reflux management and inflammatory bowel disease to motility disorders and hepatic conditions.
Brands registered in
Gastroenterology The top brands registered in this area are: — ASACOL — AUSFAM — BYLVAY — COLAZIDE — DIPENTUM — DULCOLAX — ESOMEPRAZOLE — GASTREX — GIVLAARI — IQIRVO — JORVEZA — LAX-TAB
Sponsor landscape
The gastroenterology market is supported by 129 active sponsors. Leading sponsors include Arrotex Pharmaceuticals, AFT Pharmaceuticals, Fresenius Kabi, Torrent, Viatris, Aspen Pharmacare, Sandoz and MedTAS.
PBS and regulatory activity
Within this area, 27 brands have PBS-listed items, with the latest PBS schedule dated 1 May 2026. Recent regulatory activity includes a latest PBAC outcome recorded on 1 December 2025 and a latest AusPAR dated 18 March 2025. To date, 23 brands in gastroenterology have PBAC outcomes on record and 9 brands have AusPARs on record.